Today's Rundown Featured Story | | | Friday, May 1, 2020 Days after U.S. officials reported the first positive controlled data for Gilead's remdesivir in COVID-19, the FDA has given the drug an emergency use authorization. |
|
|---|
|
Top Stories Thursday, April 30, 2020 Changes in telehealth reimbursement and federal relief funding might not be enough to bolster many primary care practices during the COVID pandemic. Low patient volume and inconsistent reimbursement are hampering cash flow, resulting in furloughs and layoffs, according to a survey of 1,000 primary care clinicians in 48 states and Washington D.C. Friday, May 1, 2020 Moderna Therapeutics has partnered with the federal government to create an mRNA-based COVID-19 vaccine it hopes to speed through clinical trials and right into production. One problem with that plan? The partners couldn't find a manufacturer willing to take on the risks for little financial reward—until now. Friday, May 1, 2020 At the J.P. Morgan Healthcare Conference in January—back when few could predict the looming destruction of COVID-19—Amgen CEO Bob Bradway vowed the company would find new ways to make its $13.4 billion acquisition of Celgene’s psoriasis drug Otezla worth the investment. Now, COVID-19 is presenting one such opportunity. Friday, May 1, 2020 COVID-19 may be making the case for accelerating the move to more value-based models of care. Friday, May 1, 2020 Gilead Sciences scored a massive win earlier this week with its first positive data readout for investigational candidate remdesivir in treating patients with severe COVID-19. Gilead already has its own supply of the drug humming in anticipation of high demand, but opportunities are out there for a partner to join in. Friday, May 1, 2020 The successful activation of T cells is critical to the immune system's ability to clear infections. A retrospective study in China found that COVID-19 patients had remarkably low T-cell counts in their blood, while some pro-inflammatory cytokines such as IL-6—which Roche’s Actemra targets—were elevated. Friday, May 1, 2020 Hospital and provider groups applauded a series of changes from CMS aimed at increasing regulatory flexibility for providers fighting the COVID-19 pandemic. Friday, May 1, 2020 The National Institutes of Health kicked off what it describes as a “Shark Tank”-like effort to select and fund new diagnostic tests for the novel coronavirus, and its offering a total of $1.5 billion to be divvied up among the winners. Friday, May 1, 2020 A new study out of China has tied T cell activation to Roche's IL-6 inhibitor Actemra, which has shown some early effect in treating cytokine storm in severe COVID-19 patients. Friday, May 1, 2020 Two women were charged with thefts from Central Indiana Cancer Center that included stolen morphine. Friday, May 1, 2020 The European Medicines Agency has begun a rolling review of data on Gilead’s remdesivir, positioning it to cut the time it takes to decide whether to approve the drug in COVID-19 patients. Friday, May 1, 2020 AbbVie may be working through COVID-19, but it's pressing ahead with its Allergan merger, too—and taking stock of products hit by pandemic lockdowns. That puts Allergan’s aesthetics business top of mind, but AbbVie CEO Rick Gonzalez figures customers are ready and able to return quickly for treatment. Friday, May 1, 2020 Inovio Pharmaceuticals’ stock has climbed higher and higher over the past month since it said it was working on a speedy COVID-19 vaccine. Friday, May 1, 2020 Pfizer and partner BioNTech are right in the middle of one of the most important vaccine trials in the world right now, but that doesn’t mean the Big Pharma is taking its eyes off the inoculation ball elsewhere. |
|
.png)
